How to Approach Relapsed DLBCL After CAR-T Therapy

This week, “The Fellow on Call” hosts Ronak Mistry, DO; Vivek Patel, MD; and Dan Hausrath, MD; bring you the second part of their discussion on how to approach primary refractory diffuse large B-cell lymphoma (DLBCL).

Last time, the hosts talked about the role of chimeric antigen receptor (CAR)-T therapy versus autologous transplant, how to approach treatment in patients who are poor candidates for autologous CAR-T, and more.

Building upon their conversation, this week’s episode discussed treatment with selective antibodies against CD19, how to approach relapsed disease after chimeric antigen receptor (CAR)-T therapy, the use of bispecific T-cell engager therapy, and the role of allogeneic hematopoietic stem cell transplant.

This podcast originally appeared on thefellowoncall.com.